{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T09:26:58Z","timestamp":1775035618651,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.bmcl.2022.128942","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T11:32:34Z","timestamp":1660390354000},"page":"128942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Combining monoamine oxidase B and semicarbazide-sensitive amine oxidase enzyme inhibition to address inflammatory disease"],"prefix":"10.1016","volume":"74","author":[{"given":"Jonathan S.","family":"Foot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Buson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandar","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison D.","family":"Findlay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan D.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig I.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tin","family":"Yow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Jarolimek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2022.128942_b0005","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1073\/pnas.85.13.4934","article-title":"cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties","volume":"85","author":"Bach","year":"1988","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.bmcl.2022.128942_b0010","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1126\/science.1529341","article-title":"A 90-kilodalton endothelial cell molecule mediating lymphocyte binding in humans","volume":"257","author":"Salmi","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2022.128942_b0015","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/0923-2494(93)80060-C","article-title":"Vascular adhesion protein-1 (VAP-1) - a new adhesion molecule recruiting lymphocytes to sites of inflammation","volume":"144","author":"Jalkanen","year":"1993","journal-title":"Res Immunol"},{"key":"#cr-split#-10.1016\/j.bmcl.2022.128942_b0020.1","doi-asserted-by":"crossref","unstructured":"Jinsmaa Y, Florang VR, Rees JN, Anderson DG, Strack S, Doorn JA. Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate. Chem Res Toxicol. 2009, 22, 835. doi: 10.1021\/tx800405v. PMID: 19388687","DOI":"10.1021\/tx800405v"},{"key":"#cr-split#-10.1016\/j.bmcl.2022.128942_b0020.2","doi-asserted-by":"crossref","unstructured":"Sena CM, Matafome P, Cris\u00f3stomo J, et al. Methylglyoxal promotes oxidative stress and endothelial dysfunction. Pharmacol Res. 2012, 65, 497. doi: 10.1016\/j.phrs.2012.03.004. PMID: 22425979","DOI":"10.1016\/j.phrs.2012.03.004"},{"key":"#cr-split#-10.1016\/j.bmcl.2022.128942_b0020.3","doi-asserted-by":"crossref","unstructured":"Zhang Y, Yang Y, He X, et al. The cellular function and molecular mechanism of formaldehyde in cardiovascular disease and heart development. J Cell Mol Med. 2021, 25, 5358. doi: 10.1111\/jcmm.16602. PMID: 33973354","DOI":"10.1111\/jcmm.16602"},{"key":"#cr-split#-10.1016\/j.bmcl.2022.128942_b0020.4","doi-asserted-by":"crossref","unstructured":"G\u00f6tz ME, K\u00fcnig G, Riederer P, Youdim MB. Oxidative stress: free radical production in neural degeneration. Pharmacol Ther. 1994, 63, 37. doi: 10.1016\/0163-7258(94)90055-8. PMID: 7972344.","DOI":"10.1016\/0163-7258(94)90055-8"},{"key":"10.1016\/j.bmcl.2022.128942_b0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10571-018-0632-3","article-title":"Dopamine: functions, signalling, and association with neurological diseases","volume":"39","author":"Klein","year":"2019","journal-title":"Cell Mol Neurobiol"},{"key":"#cr-split#-10.1016\/j.bmcl.2022.128942_b0030.1","unstructured":"Cesura AM, Borroni E, Gottowik J, et al. Lazabemide for the treatment of Alzheimer's disease: rationale and therapeutic perspectives. Adv Neurol. 1999, 80, 521. PMID: 10410766"},{"key":"#cr-split#-10.1016\/j.bmcl.2022.128942_b0030.2","doi-asserted-by":"crossref","unstructured":"Behl T, Kaur D, Sehgal A, et al. Role of monoamine oxidase activity in alzheimer's disease: an insight into the therapeutic potential of inhibitors. Molecules 2021, 26, 3724. doi: 10.3390\/molecules26123724. PMID: 34207264.","DOI":"10.3390\/molecules26123724"},{"key":"10.1016\/j.bmcl.2022.128942_b0035","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.3390\/ijms22105313","article-title":"Dopaminergic receptor targeting in multiple sclerosis: is there therapeutic potential?","volume":"22","author":"Melnikov","year":"2021","journal-title":"Int J Mol Sci"},{"key":"#cr-split#-10.1016\/j.bmcl.2022.128942_b0040.1","doi-asserted-by":"crossref","unstructured":"Becchi S, Buson A, Foot J, Jarolimek W, Balleine BW. Inhibition of semicarbazide-sensitive amine oxidase\/vascular adhesion protein-1 reduces lipopolysaccharide-induced neuroinflammation. Br J Pharmacol. 2017, 174, 2302. doi: 10.1111\/bph.13832. PMID: 28437839","DOI":"10.1111\/bph.13832"},{"key":"#cr-split#-10.1016\/j.bmcl.2022.128942_b0040.2","doi-asserted-by":"crossref","unstructured":"Becchi S, Buson A, Balleine BW. Inhibition of vascular adhesion protein 1 protects dopamine neurons from the effects of acute inflammation and restores habit learning in the striatum. J Neuroinflammation. 2021, 18, 233. doi: 10.1186\/s12974-021-02288-8. PMID: 34654450.","DOI":"10.1186\/s12974-021-02288-8"},{"key":"10.1016\/j.bmcl.2022.128942_b0045","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.3390\/ijms22073365","article-title":"SSAO\/VAP-1 in cerebrovascular disorders: A potential therapeutic target for stroke and Alzheimer's disease","volume":"22","author":"Unzeta","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmcl.2022.128942_b0050","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/BF02263478","article-title":"MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease","volume":"1","author":"Zreika","year":"1989","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"10.1016\/j.bmcl.2022.128942_b0055","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12931-015-0200-z","article-title":"Effects of an anti-inflammatory VAP-1\/SSAO inhibitor, PXS-4728A, on pulmonary neutrophil migration","volume":"16","author":"Schilter","year":"2015","journal-title":"Respir Res"},{"key":"10.1016\/j.bmcl.2022.128942_b0060","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1039\/9781788015783-00145","article-title":"Inhibition of LOXL2 and other lysyl oxidase (like) enzymes: intervention at the core of fibrotic pathology","author":"Findlay","year":"2020","journal-title":"Anti-fibrotic Drug Discov RSC publishing"},{"key":"10.1016\/j.bmcl.2022.128942_b0065","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.1021\/jm8011867","article-title":"Structural and mechanistic studies of mofegiline inhibition of recombinant human monoamine oxidase B","volume":"51","author":"Milczek","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128942_b0070","doi-asserted-by":"crossref","first-page":"9874","DOI":"10.1021\/acs.jmedchem.9b01283","article-title":"Identification and optimization of mechanism-based fluoroallylamine inhibitors of lysyl oxidase-like 2\/3","volume":"62","author":"Findlay","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128942_b0075","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1016\/j.bmcl.2012.04.111","article-title":"The discovery and development of selective 3-fluoro-4-aryloxyallylamine inhibitors of the amine oxidase activity of semicarbazide-sensitive amine oxidase\/vascular adhesion protein-1 (SSAO\/VAP-1)","volume":"22","author":"Foot","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2022.128942_b0080","first-page":"99","article-title":"The making of a user friendly MAOI diet","volume":"57","author":"Gardner","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.bmcl.2022.128942_b0085","first-page":"720","article-title":"Demystifying serotonin syndrome (or serotonin toxicity)","volume":"64","author":"Foong","year":"2018","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.bmcl.2022.128942_b0090","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/clpt.1994.175","article-title":"Kinetics and metabolism of p-tyramine during monoamine oxidase inhibition by mofegiline","volume":"56","author":"Huebert","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"#cr-split#-10.1016\/j.bmcl.2022.128942_b0095.1","unstructured":"Myllyl\u00e4 VV, Sotaniemi KA, Aasly J, et al. An open multicenter study of the efficacy of MDL 72,974A, a monoamine oxidase type B (MAO-B) inhibitor, in Parkinson's disease. Adv Neurol. 1993, 60, 676. PMID: 8420209"},{"key":"#cr-split#-10.1016\/j.bmcl.2022.128942_b0095.2","doi-asserted-by":"crossref","unstructured":"Marconi R, Bonnet AM, Vidailhet M, Agid Y. The IMAO-B MDL 72.974 A in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1992, 55, 1096-7. doi: 10.1136\/jnnp.55.11.1096-a. PMID: 1469412.","DOI":"10.1136\/jnnp.55.11.1096-a"},{"key":"10.1016\/j.bmcl.2022.128942_b0100","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0006-2952(92)90293-R","article-title":"Inhibition of a type B monoamine oxidase inhibitor, (E)-2-(4-fluorophenethyl)-3-fluoroallylamine (MDL-72974A), on semicarbazide-sensitive amine oxidases isolated from vascular tissues and sera of different species","volume":"43","author":"Yu","year":"1992","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmcl.2022.128942_b0105","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.tiv.2011.05.026","article-title":"High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis","volume":"25","author":"van de Water","year":"2011","journal-title":"Toxicol In Vitro"},{"key":"10.1016\/j.bmcl.2022.128942_b0110","unstructured":"For a recent example of SAR of E vs Z in a different series of fluoro allylamine inhibitors showing less activity in the E-isomer examples; see WO 2019\/180644."},{"key":"10.1016\/j.bmcl.2022.128942_b0115","doi-asserted-by":"crossref","unstructured":"This recent review covers the varied readouts of MAO A and B enzyme recovery: Tipton KF. 90 years of monoamine oxidase: some progress and some confusion. J Neural Transm (Vienna). 2018, 125, 1519. doi: 10.1007\/s00702-018-1881-5. PMID: 29637260.","DOI":"10.1007\/s00702-018-1881-5"},{"key":"10.1016\/j.bmcl.2022.128942_b0120","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.183","article-title":"Models of inflammation: carrageenan air pouch","volume":"1","author":"Fehrenbacher","year":"2021","journal-title":"Curr Protoc"},{"key":"10.1016\/j.bmcl.2022.128942_b0125","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1476-5381.2011.01302.x","article-title":"Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)","volume":"164","author":"Constantinescu","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmcl.2022.128942_b0130","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00702-007-0699-3","article-title":"Benefit of inhibiting SSAO in relapsing experimental autoimmune encephalomyelitis","volume":"114","author":"O'Rourke","year":"2007","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1016\/j.bmcl.2022.128942_b0135","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.bbi.2011.06.011","article-title":"The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE)","volume":"25","author":"Musgrave","year":"2011","journal-title":"Brain Behav Immun"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22004188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22004188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:45:51Z","timestamp":1760773551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X22004188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":33,"alternative-id":["S0960894X22004188"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128942","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combining monoamine oxidase B and semicarbazide-sensitive amine oxidase enzyme inhibition to address inflammatory disease","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128942","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"128942"}}